September 18, 2026

To
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

To
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Code: 543064

Scrip Symbol: COHANCE

Dear Sir/Madam,

Sub: Investment in Compulsorily Convertible Preferred Stock of NJ Bio Inc., USA

This is in continuation of our letter dated December 2, 2025, wherein the Company had informed regarding the approval of its Board of Directors for fund infusion by way of investment in Compulsorily Convertible Preferred Stock ("CCPS") of NJ Bio Inc., USA ("NJ Bio"), a subsidiary of the Company, up to an amount of USD 10 million. We hereby inform that the Company has remitted the aggregate consideration of USD 10 million towards subscription of new CCPS of NJ Bio.

The details required under SEBI Circular No. SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 are enclosed herewith as **Annexure A**.

Kindly take the above on record.

Thanking you.

Yours faithfully,

For **Cohance Lifesciences Limited**
(formerly, Suven Pharmaceuticals Limited)

SISIRA KUMAR MISHRA
Digitally signed by SISIRA KUMAR MISHRA
Date: 2026.09.18 18:27:00 +05'30'

Sisir K Mishra
Company Secretary & Compliance Officer

Encl: As above.

Annexure-A

Investment in Compulsorily Convertible Preferred Stock of NJ Bio Inc

Sl	Particulars	Details
a.	Name of the target entity, details in brief such as size, turnover etc.	**Name of the Target**: NJ Bio, Inc (NJ Bio) having its registered office at 251 Little Falls Drive, Wilmington, New Castle County, Delaware, 19808 and corporate office at 350 Carter Road, Princeton, NJ 08540. **Details of the Target**: NJ Bio is an Antibody Drug Conjugate ("ADC") focused Contract Research, Development, and Manufacturing Organization ("CRDMO") and one of the leading global players with end-to-end capabilities across payload-linker synthesis, bioconjugation and analytical services, providing customized ADC solutions that accelerate customers' discovery and development. **Turnover**: • CY2023: USD 20.6 million • CY2024: USD 32.6 million • CY2025: USD 23.5 million
b.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	The transaction would fall within related party transaction, as NJ Bio is a subsidiary of the Company. The promoter/ promoter group/ group companies of the Company do not have any direct interest in NJ Bio, other than through the Company as aforesaid. The transaction is at arm's length.
c.	Industry to which the entity being acquired belongs	Pharmaceutical / Chemical Compounds CRDMO
d.	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	Cohance, along with its subsidiaries/affiliates, is engaged in the contract development, manufacture and sale of drug products and other allied activities. NJ Bio is amongst the few CRDMOs in the high growth ADC and broader 'XDC' (other conjugation-based therapies) space. This investment reinforces Cohance's commitment to the ADC space and will support NJ Bio's growth initiatives including capex .
e.	Brief details of any governmental or regulatory approvals required for the acquisition;	The transaction will be in accordance with the applicable provisions of the FEMA (Overseas Investment) Regulations, 2022 read with the rules and circulars made thereunder. Further, the Company will make applicable regulatory filings with the relevant authorities, as may be required under applicable laws.

f.	Indicative time period for completion of the acquisition;	The Company has remitted the aggregate consideration amount and expects to complete the transaction before end of September 2026.
g.	Consideration - whether cash consideration or share swap or any other form and details of the same;	Cash consideration (through internal accruals) for subscription to new Compulsorily Convertible Preference Stocks ("CCPS") of NJ Bio.
h.	Cost of acquisition and/or the price at which the shares are acquired;	The aggregate consideration is USD 10 Million for the primary subscription of 188,680 CCPS of NJ Bio at USD 53.00 per CCPS.
i.	Percentage of shareholding / control acquired and / or number of shares acquired	Upon completion of the transaction, the Company will hold 188,680 CCPS of NJ Bio which are convertible to equity shares of NJ Bio after 3 years in accordance with the terms of the definitive agreements.
j.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	**Brief background and line of business**: NJ Bio is an ADC / 'XDC' focused CRDMO and one of the leading global players with end-to-end capabilities across payload-linker synthesis, bioconjugation and ADCs characterization, providing customized ADC solutions that accelerate customers' discovery and development. **Date of Incorporation**: NJ Bio, Inc. (formerly known as NJ Biopharmaceuticals LLC), was incorporated as a limited liability company under applicable laws on 23 October 2017 in Bristol, Pennsylvania, USA, and was subsequently converted to an incorporated corporation, in the name of NJ Bio, Inc., on 01 August 2022 in Delaware, USA. **Turnover of last 3 years**: • CY2023: USD 20.6 million • CY2024: USD 32.6 million • CY2025: USD 23.5 million **Country in which the entity has presence**: Other than USA, NJ Bio has business operations in India through a subsidiary entity, NJBIO India Pharmaceutical Private Limited.